Please login to the form below

Not currently logged in

Arcus Biosciences

This page shows the latest Arcus Biosciences news and features for those working in and with pharma, biotech and healthcare.

Gilead and Arcus drop A2R inhibitor in prostate cancer following early data analysis

Gilead and Arcus drop A2R inhibitor in prostate cancer following early data analysis

Gilead Sciences and Arcus Biosciences have decided to ‘deprioritise’ the further development of their A2 receptor antagonist, etrumadenant, in metastatic castrate-resistant prostate cancer (mCRPC) after reviewing radiographic progression-free

Latest news

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Acquisition. $463m. Precision BioSciences/. Gilead Sciences. ARCUS technology; targeting in vivo elimination of. ... The agreement is for the development of therapies to eliminate the hepatits B virus (HBV) in vivo using the genome editing platform ARCUS.

  • Pharma deals continue to slide Pharma deals continue to slide

    Arcus, a privately owned US immuno-oncology company, may have to do the same following its deal to license a monoclonal antibody from the Chinese companies WuXi Biologics and Gloria Pharmaceuticals. ... 1, 410 (upfront 80). WuXi Biologics and Gloria

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts


Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...